Oct 22 (Reuters) - Botanix Pharmaceuticals Ltd BOT.AX :
* ANNOUNCES DATA FROM BTX 1503 PHASE 2 RANDOMISED, DOUBLE BLIND, VEHICLE-CONTROLLED ACNE PATIENT STUDY
* STUDY SAW NO SERIOUS ADVERSE EVENTS AND VERY LOW INCIDENCE OF TREATMENT-RELATED ADVERSE EVENTS
* IS MOVING FORWARD WITH ITS CLINICAL PROGRAM WITH A PHASE 2 FDA MEETING
* PRIMARY ENDPOINT OF REDUCTION IN INFLAMMATORY LESIONS DID NOT ACHIEVE STATISTICAL SIGNIFICANCE
* SECONDARY ENDPOINT OF REDUCTION IN NON-INFLAMMATORY ENDPOINTS, WAS STATISTICALLY SIGNIFICANT